Benzinga

Benzinga

Benzinga

lundi, août 24

Corcept Therapeutics Inc

CORTNASDAQ
Trade with Public
Trade with Public
$123.24
0.990.81%
À la clôture: Aug 24, 5:00 PM EST
$123.35
0.110.09%
Après les heures: 6:15 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Corcept Therapeutics Financials

Corcept Therapeutics (CORT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know

Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.
Mohd Haider

PRO
Corcept Therapeutics Raises FY2026 Sales Guidance from $950.000M-$1.050B to $1.100B-$1.200B vs $1.008B Est

Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $950.000 million-$1.050 billion to $1.100 billion-$1.200 billion vs $1.008 billion estimate.
Benzinga Newsdesk

PRO
Corcept Therapeutics Q2 EPS $0.36 Beats $(0.00) Estimate, Sales $256.147M Beat $219.988M Estimate

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $(0.00) by Infinity percent. This is a 24.14 percent increase over earnings of $0.29 per
Benzinga Newsdesk

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept shares rise after Phase 2 ALS data shows 87% lower death risk; earnings miss, revenue shortfall, and raised 2026 sales outlook.
Vandana Singh

PRO
Corcept Therapeutics Raises FY2026 Sales Guidance from $900.000M-$1.000B to $950.000M-$1.050B vs $941.180M Est

Corcept Therapeutics (NASDAQ:CORT) raises FY2026 sales outlook from $900.000 million-$1.000 billion to $950.000 million-$1.050 billion vs $941.180 million estimate.
Benzinga Newsdesk

PRO
Corcept Therapeutics Q1 EPS $(0.30) Misses $(0.16) Estimate, Sales $164.903M Miss $192.510M Estimate

Corcept Therapeutics (NASDAQ:CORT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.16) by 87.5 percent. This is a 276.47 percent decrease over earnings of $0.17 per share
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved